Immunohistochemical assessment of Ki67 with antibodies SP6 and MIB1 in primary breast cancer: a comparison of prognostic value and reproducibility.

Maria Ekholm; Sanda Beglerbegovic; Dorthe Grabau; Kristina Lövgren; Per Malmström; Linda Werner Hartman; Mårten Fernö

doi:10.1111/his.12392

Immunohistochemical assessment of Ki67 with antibodies SP6 and MIB1 in primary breast cancer: a comparison of prognostic value and reproducibility.

Maria Ekholm, Sanda Beglerbegovic, Dorthe Grabau, Kristina Lövgren, Per Malmström, Linda Werner Hartman, Mårten Fernö

Research output: Contribution to journal › Article › peer-review

Abstract

To compare the antibodies, SP6 and MIB1, for assessment of Ki67 in primary breast cancer, regarding prognostic value and reproducibility.

Original language	English
Pages (from-to)	252-260
Journal	Histopathology
Volume	65
Issue number	2
DOIs	https://doi.org/10.1111/his.12392
Publication status	Published - 2014

Bibliographical note

The information about affiliations in this record was updated in December 2015.
The record was previously connected to the following departments: Cancer Epidemiology (013007100), Pathology, (Lund) (013030000), Oncology, MV (013035000)

Subject classification (UKÄ)

Cell and Molecular Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/his.12392

http://www.ncbi.nlm.nih.gov/pubmed/24527721?dopt=Abstract

1 Doctoral Thesis (compilation)

Prognostic and Predictive Markers in Primary Breast Cancer - Quality Assurance and Long-term Effects of Adjuvant tamoxifen Treatment
Ekholm, M., 2018, Lund: Lund University: Faculty of Medicine. 138 p.
Research output: Thesis › Doctoral Thesis (compilation)

Open Access
File

Cite this

@article{85d488d195dd4950a0449ca45728c478,

title = "Immunohistochemical assessment of Ki67 with antibodies SP6 and MIB1 in primary breast cancer: a comparison of prognostic value and reproducibility.",

abstract = "To compare the antibodies, SP6 and MIB1, for assessment of Ki67 in primary breast cancer, regarding prognostic value and reproducibility.",

author = "Maria Ekholm and Sanda Beglerbegovic and Dorthe Grabau and Kristina L{\"o}vgren and Per Malmstr{\"o}m and {Werner Hartman}, Linda and M{\aa}rten Fern{\"o}",

note = "The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Cancer Epidemiology (013007100), Pathology, (Lund) (013030000), Oncology, MV (013035000)",

year = "2014",

doi = "10.1111/his.12392",

language = "English",

volume = "65",

pages = "252--260",

journal = "Histopathology",

issn = "0309-0167",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - Immunohistochemical assessment of Ki67 with antibodies SP6 and MIB1 in primary breast cancer: a comparison of prognostic value and reproducibility.

AU - Ekholm, Maria

AU - Beglerbegovic, Sanda

AU - Grabau, Dorthe

AU - Lövgren, Kristina

AU - Malmström, Per

AU - Werner Hartman, Linda

AU - Fernö, Mårten

N1 - The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Cancer Epidemiology (013007100), Pathology, (Lund) (013030000), Oncology, MV (013035000)

PY - 2014

Y1 - 2014

N2 - To compare the antibodies, SP6 and MIB1, for assessment of Ki67 in primary breast cancer, regarding prognostic value and reproducibility.

AB - To compare the antibodies, SP6 and MIB1, for assessment of Ki67 in primary breast cancer, regarding prognostic value and reproducibility.

U2 - 10.1111/his.12392

DO - 10.1111/his.12392

M3 - Article

C2 - 24527721

SN - 0309-0167

VL - 65

SP - 252

EP - 260

JO - Histopathology

JF - Histopathology

IS - 2

ER -

Immunohistochemical assessment of Ki67 with antibodies SP6 and MIB1 in primary breast cancer: a comparison of prognostic value and reproducibility.

Abstract

Bibliographical note

Subject classification (UKÄ)

UN SDGs

Access to Document

Fingerprint

Research output

Prognostic and Predictive Markers in Primary Breast Cancer - Quality Assurance and Long-term Effects of Adjuvant tamoxifen Treatment

Cite this